Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA consults on regulatory acceptance of "3R" alternatives to animal studies

This article was originally published in SRA

Executive Summary

The European Medicines Agency is seeking stakeholder feedback concerning the revision of its position on the replacement of animal studies with alternative models for drug testing1,2. The exercise, it is expected, will lead to the development of a clear process for the regulatory acceptance of all "3R" (replacement, reduction and refinement) alternative methods for non-clinical testing of medicinal products.

You may also be interested in...



How To Manage Pharmacovigilance Inspections In A Globalized World

As companies undergo pharmacovigilance inspections from a growing multitude of regulatory authorities from around the globe, a senior pharmaceutical industry executive discusses how her company has been handling this complex and challenging task.

Inspection Interviews: Dutch Official Addresses Frustrations And Misconceptions

While inspection interviews can be stressful for drug firms, a Dutch pharmacovigilance inspector reassures companies that any responses made during the process cannot undo any good work they have already done. And they can also correct any wrong answers later on.

How Saudi Arabia Differs From The EU On Pharmacovigilance Inspections

The Saudi Food & Drug Authority looks at the number of individual case safety reports (ICSRs) submitted by a company, among other risk-based factors, when drawing up its list for routine pharmacovigilance inspections.

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel